Stoke Therapeutics Inc (NASDAQ: STOK) is 15.14% higher on its value in year-to-date trading and has touched a low of $4.09 and a high of $17.58 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The STOK stock was last observed hovering at around $12.60 in the last trading session, with the day’s gains setting it 0.1%.
Currently trading at $12.70, the stock is 24.26% and 13.30% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.01 million and changing 0.79% at the moment leaves the stock -2.48% off its SMA200. STOK registered 172.82% gain for a year compared to 6-month loss of -6.48%. The firm has a 50-day simple moving average (SMA 50) of $11.1818 and a 200-day simple moving average (SMA200) of $13.01795.
The stock witnessed a 10.53% gain in the last 1 month and extending the period to 3 months gives it a -1.24%, and is 20.84% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.57% over the week and 7.86% over the month.
Stoke Therapeutics Inc (STOK) has around 110 employees, a market worth around $672.68M and $16.74M in sales. Profit margin for the company is -629.86%. Distance from 52-week low is 210.51% and -27.76% from its 52-week high. The company has generated returns on investments over the last 12 months (-44.85%).
with sales reaching $4.2M over the same period.The EPS is expected to grow by 14.75% this year, but quarterly earnings will post 98.32% year-over-year. Quarterly sales are estimated to grow 49.89% in year-over-year returns.
175.0 institutions hold shares in Stoke Therapeutics Inc (STOK), with institutional investors hold 112.35% of the company’s shares. The shares outstanding are 52.94M, and float is at 43.07M with Short Float at 20.32%. Institutions hold 107.10% of the Float.
The top institutional shareholder in the company is SKORPIOS TRUST with over 10.84 million shares valued at $146.5 million. The investor’s holdings represent 23.4474 of the STOK Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 5.41 million shares valued at $73.08 million to account for 11.6963 of the shares outstanding. The other top investors are LYNX1 CAPITAL MANAGEMENT LP which holds 5.19 million shares representing 11.212 and valued at over $70.05 million, while REDMILE GROUP, LLC holds 10.2084 of the shares totaling 4.72 million with a market value of $63.78 million.
Stoke Therapeutics Inc (STOK) Insider Activity
The most recent transaction is an insider sale by Skorpios Trust, the company’s 10% Owner. SEC filings show that Skorpios Trust sold 2,000,000 shares of the company’s common stock on Dec 23 ’24 at a price of $11.50 per share for a total of $23.0 million. Following the sale, the insider now owns 6.91 million shares.
Still, SEC filings show that on Dec 09 ’24, Ticho Barry (CHIEF MEDICAL OFFICER) disposed off 2,586 shares at an average price of $12.99 for $33596.0. The insider now directly holds 44,746 shares of Stoke Therapeutics Inc (STOK).
